JAK1-IN-17 (Compound 31) is a highly selective inhibitor of JAK1 with a K i of 1.9 nM. JAK1-IN-17 exhibits a low whole blood shift, which allows maintaining good whole blood potency. JAK1-IN-17 is also a nitrile-containing analogue with consistent, yet weak reversible inhibition of CYP3A4 using a midazolam probe ( IC 50 = 7.9 μM). JAK1-IN-17 can be studied in cancer research.
Products | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Signaling Pathways > JAK
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.